DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

DAIC

MARCH 7, 2024

Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. These patients saw more than a 17% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (2.9%

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105

DAIC

JULY 25, 2024

FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heart failure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

DAIC

JULY 1, 2024

Adamson, MD, MSc, FACC, FESC, FRCP (Ed ) has been appointed as Chief Medical Officer, Bonnie Handke, RN, MBA will assume the role of Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics, and Jennifer E. Englund recently joined as Senior Vice President of Global Clinical Affairs. Handke earned an MBA from St.

Reimbursement 105

Reimbursement RN Heart Failure Laboratory 105

HeartRhythm

JANUARY 2, 2024

In patients with heart failure (HF) undergoing left bundle branch area pacing (LBBAP) for cardiac resynchronization therapy (CRT) without a defibrillator (e.g., However, in some countries CRT is not reimbursed if a 3-lead device is not used, and the clinical impact of avoiding this additional lead has not been established.

Reimbursement 40

Reimbursement Defibrillator Pacemaker Heart Failure 40

DAIC

JULY 31, 2024

In its announcement about the workbook, ACC noted that cardiologists use digital devices and wearable technology to remotely monitor their patients for a variety of chronic cardiovascular diseases, including heart failure, coronary artery disease, vascular disease and atrial fibrillation. Food and Drug Administration authorization.

Reimbursement 98

Reimbursement Technology Coronary Artery Disease Best Practices 98

DAIC

JANUARY 16, 2024

There, he served as an investigator in many high-profile clinical trials, including several significant structural heart studies. Dr. Shreenivas is a frequent speaker at major scientific meetings and has been widely published in peer-reviewed journals across the structural heart, heart failure, and coronary arenas.

Bicuspid/Mitral 59

Bicuspid/Mitral Heart Failure Catheterization Laboratory Innovation 59